Influenza epidemics are estimated to result in 3–5 million cases of severe illness and 290.000–650.000 deaths per year. Due to the limited anti-influenza drugs available and the emergence of drug-resistant viral strains, innovative influenza therapeutics directed at new targets and/or with novel mechanisms of action are urgently needed.
In an effort to discover novel anti-influenza agents, several molecules of our diverse in-house library were screened against a panel of different influenza virus strains. Following this approach, we identified structurally novel 4,4-disubstituted N-benzylpiperidine compounds as interesting hit compounds that display antiviral activity against influenza virus A/H1N1 in the low micromolar range. To investigate the structure–activity relationships, several analogues were easily synthesized, by a one-step Ugi four-component reaction, from commercially available amines, isocyanides, N-substituted piperidones, and a variety of amino acids as carboxylic acid components. The mechanism of action of the most active compounds was examined, taking into account time-of-addition, resistance selection, and functional assays for HA-mediated binding or membrane fusion, suggesting that the compounds inhibit HA-mediated fusion. Mutational and computational simulations proposed an unexplored new cavity near the fusion peptide as the putative binding site for these N-benzylpiperidine analogues. Interestingly, a pi-stacking interaction between the N-benzylpiperidine moiety with a Phe residue of the fusion peptide represents one of the most relevant ligand–protein interactions. These compounds may be considered useful research tools to explore a new cavity at HA for the design of novel small-molecule fusion influenza inhibitors.
The synthesis, biological evaluation, mechanism of action, and computational studies of these N-benzylpiperidine derivatives will be reported in this communication.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).